UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000053865
Receipt number R000061475
Scientific Title Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting
Date of disclosure of the study information 2024/03/14
Last modified on 2024/03/14 17:59:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting

Acronym

Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting

Scientific Title

Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting

Scientific Title:Acronym

Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting

Region

Japan


Condition

Condition

Patients receiving highly or moderately emetogenic chemotherapy

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine Pneumology
Hematology and clinical oncology Gastrointestinal surgery Hepato-biliary-pancreatic surgery
Breast surgery Obstetrics and Gynecology Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of fosnetupitant in patients receiving highly or moderately emetogenic chemotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1)Common Terminology Criteria for Adverse Events (CTCAE) v5.0
2)MASCC Antinausea and vomiting Tool (MAT)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Adult
2)Patients receiving highly or moderately emetogenic chemotherapy

Key exclusion criteria

patients with severe dementia

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Kosuke
Middle name
Last name Nishizawa

Organization

Toho University Sakura Medical Center

Division name

Department of Pharmacy

Zip code

285-8741

Address

564-1, Shimoshizu, Sakura City, Chiba

TEL

043-462-8811

Email

k-nishizawa@med.toho-u.ac.jp


Public contact

Name of contact person

1st name Kosuke
Middle name
Last name Nishizawa

Organization

Toho University Sakura Medical Center

Division name

Department of Pharmacy

Zip code

285-8741

Address

564-1, Shimoshizu, Sakura City, Chiba

TEL

043-462-8811

Homepage URL


Email

k-nishizawa@med.toho-u.ac.jp


Sponsor or person

Institute

Toho University Sakura Medical Center

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee of Toho University, Sakura Medical Center

Address

564-1, Shimoshizu, Sakura City, Chiba

Tel

043-462-8811

Email

sakura.rinri@ext.toho-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 03 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 12 Month 15 Day

Date of IRB

2023 Year 12 Month 15 Day

Anticipated trial start date

2024 Year 03 Month 14 Day

Last follow-up date

2026 Year 10 Month 25 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

retrospective study


Management information

Registered date

2024 Year 03 Month 14 Day

Last modified on

2024 Year 03 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061475


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name